Published in Cardiovascular Business Week, December 14th, 2004
In the third quarter, MacroPore said it continued to shift its business focus toward its regenerative cell technology. During this time, MacroPore received its first patent related to stem cells from adipose tissue; received its first regulatory clearance related to its regenerative cell technology system; expanded its National Institute of Health research grant funding; and reported positive preclinical study results in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.